Search

Your search keyword '"Della Corte, Carminia Maria"' showing total 171 results

Search Constraints

Start Over You searched for: Author "Della Corte, Carminia Maria" Remove constraint Author: "Della Corte, Carminia Maria"
171 results on '"Della Corte, Carminia Maria"'

Search Results

151. PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype.

152. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.

153. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.

154. The use of ultrasound in the evaluation of postoperative pneumothorax and lung re-expansion in patients after lung resection.

155. Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?

156. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.

157. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.

158. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.

159. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.

160. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer.

161. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'.

162. Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study.

163. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.

164. Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis.

165. Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota.

166. Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.

167. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.

168. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.

169. Mechanisms of resistance to EGFR-targeted drugs: lung cancer.

170. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

171. Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.

Catalog

Books, media, physical & digital resources